Orthofix Medical OFIX
- Market cap
- $399.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.5×
- EV/EBIT
- 298×
- Revenue, 12 months
- $833.2M
- +3% on a year ago
- Net margin
- −7.4%
- Free cash flow yield
- −7.0%
Orthofix Medical trades at 0.5× sales. Its trailing earnings are negative, so it has no PE. Revenue was $833.2M over the last twelve months, up 3% on a year earlier with a −7% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $184M+61% | $200.4M+64% | $188.6M+8% | $198.6M+6% | $196.6M+7% | $215.7M+8% | $193.6M+3% | $203.1M+2% | $205.6M+5% | $219.9M+2% | $196.7M+2% | $210.9M+4% | |
| Cost of revenue | $64.2M+110% | $63.8M+93% | $61.4M−5% | $63.9M−5% | $61.6M−4% | $66.8M+5% | $72M+17% | $63.6M−0% | $57.1M−7% | $63.6M−5% | $57.2M−21% | $61.2M−4% |
| Gross profit | $119.8M+44% | $136.6M+53% | $127.2M+15% | $134.7M+13% | $135.1M+13% | $148.8M+9% | $121.6M−4% | $139.5M+4% | $148.5M+10% | $156.3M+5% | $139.5M+15% | $149.7M+7% |
| R&D | $18.6M+55% | $18.9M+44% | $19.5M−16% | $18M−7% | $17.3M−7% | $18.8M−1% | $19.8M+1% | $15.9M−12% | $14.8M−15% | $15.4M−18% | $15.3M−23% | $15.9M+0% |
| SG&A | $122.1M+63% | $132.3M+56% | $131.7M−8% | $134.2M+1% | $130.1M+7% | $136.5M+3% | $133M+1% | $136.5M+2% | $148.1M+14% | $136.8M+0% | $134.9M+2% | $138M+1% |
| −$24.4M+323% | −$18.3M+66% | −$29.3M−51% | −$24.9M−32% | −$18.9M−23% | −$11.5M−37% | −$48.9M+67% | −$16M−36% | −$17M−10% | $494K | −$14.4M−71% | −$8.1M−49% | |
| Interest expense | $1.6M+469% | $4.5M+1865% | $4.6M+254% | $4.9M+290% | $5.2M+231% | $14.9M+232% | $4.5M−1% | $4M−20% | $4.7M−10% | $4.4M−71% | $5.7M+26% | $6.1M+54% |
| Pre-tax income | −$28.4M+203% | −$22M+216% | −$35.2M−42% | −$32.4M−15% | −$26.6M−6% | −$29.7M+35% | −$52.1M+48% | −$14.2M−56% | −$22.3M−16% | −$2.2M−93% | −$20.8M−60% | −$15M+5% |
| $472K−65% | $125K+67% | $851K+39% | $1.1M−28% | $751K+59% | −$564K | $961K+13% | −$142K | $533K−29% | $30K | $74K−92% | $801K | |
| Net income | −$28.9M+169% | −$22.2M+214% | −$36M−41% | −$33.4M−15% | −$27.4M−5% | −$29.1M+31% | −$53.1M+47% | −$14.1M−58% | −$22.8M−17% | −$2.2M−92% | −$20.9M−61% | −$15.8M+12% |
| −$0.77+45% | −$0.60+71% | −$0.95−44% | −$0.88−18% | −$0.71−8% | −$0.75+25% | −$1.35+42% | −$0.36−59% | −$0.57−20% | −$0.06−92% | −$0.52−62% | −$0.39+8% | |
| 37.2M+85% | 37.1M+84% | 37.7M+6% | 38M+3% | 38.5M+3% | 38.7M+4% | 39.2M+4% | 39.5M+4% | 39.8M+3% | 40M+3% | 40.5M+3% | 40.9M+4% |
Net income: 3 periods, Q4 FY10 to Q4 FY11: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY10 to Q4 FY19: share-days: the 12-month average less the 9-month, weighted by days. 9 periods, Q4 FY13 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Orthofix Medical's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OFIXOrthofix Medical | $399.6M | n/m | 105× | 0.5× | +3% | −7.4% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| MDXGMimedx | $569.9M | 97.8× | 21.1× | 1.6× | −2% | 1.8% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| MOVMovado | $701.9M | 17.5× | 13.3× | 1.0× | +5% | 6.0% | |
| PDEXPro DEX | $199.3M | 15.1× | 16.6× | 2.6× | +16% | 17.6% | |
| IRMDIradimed | $1.1B | 47.9× | 41.4× | 12.7× | +11% | 26.7% | |
| STAAStaar Surgical | $1.1B | 323× | 143× | 3.3× | +51% | 1.1% | |
| BVSBioventus | $1.3B | 19.4× | 27.2× | 2.2× | +3% | 9.4% | |
| Peer median | $552.7M | 22.3× | 24.1× | 2.0× | +4% | 7.8% |
More on Orthofix Medical
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .